Drug Research
Drug Discovery & Development

BioTrinity 2013 - European Biopartnering and Investment Conference - May 14-16, 2013

Published 13 May 2013 | By Biovian

BioTrinity is the premier European Biopartnering and Investment Conference, partnering R&D companies with big pharma and more biomedical investors than any other European partnering conference. Check out who else is coming, we expect about 850 delegates including nearly 80 investment firms, hear what delegates say about BioTrinity, the expert discussion panels, and which 90 companies will be presenting in the showcase.

Where Great Minds and Smart Money meet Under One Roof

Meet the key licensing contacts from big pharma including AbbVie, Amgen, AstraZeneca, Boehringer, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GE, GSK, Ipsen, J&J, Janssen R&D, Linde Healthcare, MSD, Novartis, Novo Nordisk, Shire, Pfizer, Takeda, Teijin, UCB as well as Vertex, Genus, EUSA, Nordic Pharma, Mercury and other senior BD&L execs

Meet 100 delegates from active VC and Corporate Venture firms including MedImmune Ventures, SR One, Shire Strategic Investment, AbbVie Biotech Ventures, Mitsui & Co., MPHVM, Norgine Investment Fund, Novartis Venture Fund, Takeda Ventures, Boehringer Ingelheim Ventures, Inventages, Amorepacific Ventures as well as Syncona, Index, Sofinnova and many international VCs

Meet a hand-picked crop of early-stage companies you haven't seen elsewhere

Meet the senior execs who can complete the value chain for your business

Deploying EBD Group's partneringONE®, the industry gold-standard partnering system with entirely private partnering:


For more information please click here